Organ Transplant Immunosuppressant Drugs Market to be suppressed by Dearth of Donor Organs

The global organ transplant immunosuppressant drugs market is exhibiting a CAGR of -5.0% within a forecast period from 2015 to 2023. The market was registered at US$5.1 bn in 2014. It is expected to shrink to US$3.2 bn by the end of 2023, according to a research report released by Transparency Market Research. The report is titled “Organ Transplant Immunosuppressant Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Get Free Sample Research Report: http://goo.gl/3svNQB

According to the report, there are multiple factors restraining the global organ transplant immunosuppressant drugs market. The greatest restraint on this market is the imbalance in the supply and demand chain. Other factors hampering the global organ transplant immunosuppressant drugs market include the high cost of availing the procedure, coupled with unfavorable reimbursement policies, along with the advent of new and more favorable technologies.

Modern medicine has created alternatives to organ transplant immunosuppressant drugs, such as the growing use of stem cells. The market is further restricted by a severe lack of healthy donor organs.

The global organ transplant immunosuppressant drugs market is currently being boosted by the growing incidence of chronic diseases. However, the ratio of healthy donor organs to patients in need is askew, creating large-scale shortages of available organs.

The report provides a segmented analysis of the global organ transplant immunosuppressant drugs market in terms of drug class, transplant, and geography.

In terms of drug classes, the global organ transplant immunosuppressant drugs market was led by the segment of calcineurin inhibitors in 2014. In that year, the segment was calculated at US$2.3 bn. At the same time, a major number of patients are usually prescribed tacrolimus in order to maintain the schedule of the immunosuppression. This procedure shows higher potency as well as a lower rejection rate as opposed to cyclosporine.

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

90 State Street, Suite 700 Albany, NY 12207

This release was published on openPR.